Inloggen
E-mail
Wachtwoord
Paswoord weergeven
Bewaren
Bent u uw wachtwoord vergeten?
Gratis lid worden
Registreer
Registreer
Instellingen
Instellingen
Dynamische koersen 
OFFON

NEXIMMUNE, INC.

(NEXI)
uitgestelde koers. Vertraagde tijd Nasdaq - 27/10 22:00:00
11.75 USD   -6.89%
01/04NEXIMMUNE, INC. : Raymond James geeft koopadvies
MM
09/03NEXIMMUNE, INC. : Barclays bevestigt koopadvies
MM
09/03NEXIMMUNE, INC. : Een koopadvies van Cantor Fitzgerald
MM
OverzichtKoersenGrafiekenNieuwsRatingenAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproducten 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiŽle publicatiesSectornieuws
Nieuws in andere talen op NEXIMMUNE, INC.
27/09NEXIMMUNE : to Present at the 2021 Cantor Virtual Global Healthcare Conference
20/09NEXIMMUNE, INC.(NASDAQGM : NEXI) dropped from S&P Global BMI Index
10/09NexImmune to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
11/0815,079,875 Common Stock of NexImmune, Inc. are subject to a Lock-Up Agreement Ending on..
11/08Certain Options of NexImmune, Inc. are subject to a Lock-Up Agreement Ending on 11-AUG-..
09/08NEXIMMUNE : Management's Discussion and Analysis of Financial Condition and Results of Ope..
09/08Neximmune, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
09/08NEXIMMUNE, INC. : Results of Operations and Financial Condition, Regulation FD Disclosure,..
09/08NEXIMMUNE : Reports Second Quarter 2021 Financial Results and Provides Business Updates
09/08NexImmune to Explore the Use of AIM™ Direct Injection Technology in Type 1 Diabet..
09/08NexImmune, Inc. Announces a Collaboration with Yale University’s Department of Immunobi..
27/07NEXIMMUNE : to Announce Second Quarter 2021 Financial Results and Provide Corporate Update..
14/07NexImmune, Inc. Announces Executive Appointments
14/07NexImmune Strengthens Management Team with Key Appointments
21/06NEXIMMUNE, INC.(NASDAQGM : NEXI) added to S&P Global BMI Index
16/06NexImmune to Present at the Raymond James 2021 Human Health Innovation Conference
27/05NexImmune Announces Formation of Scientific Advisory Board
27/05NexImmune, Inc. Announces Formation of Scientific Advisory Board
19/05NexImmune Announces Presentation of Preliminary Phase 1/2 Clinical Data at the 2021 Ame..
17/05NEXIMMUNE : Q1 Loss Per Share Narrows From Year Ago
17/05NEXIMMUNE : Management's Discussion and Analysis of Financial Condition and Results of Ope..
17/05NEXIMMUNE, INC. : Results of Operations and Financial Condition, Financial Statements and ..
17/05NexImmune Reports First Quarter 2021 Financial Results and Recent Updates
17/05NexImmune, Inc. Announces Unaudited Earnings Results for the First Quarter Ended March ..
21/04NexImmune Appoints Chad Rubin as Senior Vice President, Corporate Affairs
21/04NexImmune, Inc. Appoints Chad Rubin as Senior Vice President, Corporate Affairs
31/03NEXIMMUNE, INC. : Results of Operations and Financial Condition, Financial Statements and ..
31/03NexImmune Reports Fiscal Year 2020 Financial Results and Recent Updates
31/03NexImmune, Inc. Reports Earnings Results for the Fiscal Year Ended December 31, 2020
31/03NEXIMMUNE : Management's Discussion and Analysis of Financial Condition and Results of Ope..
22/03NEXIMMUNE, INC.(NASDAQGM : NEXI) added to S&P TMI Index
19/03NEXIMMUNE, INC.(NASDAQGM : NEXI) added to Russell Microcap Growth Index
19/03NEXIMMUNE, INC.(NASDAQGM : NEXI) added to Russell 2500 Index
19/03NEXIMMUNE, INC.(NASDAQGM : NEXI) added to Russell 3000E Index
19/03NEXIMMUNE, INC.(NASDAQGM : NEXI) added to Russell 2000 Value Index
19/03NEXIMMUNE, INC.(NASDAQGM : NEXI) added to Russell 2500 Growth-Dynamic Index
19/03NEXIMMUNE, INC.(NASDAQGM : NEXI) added to Russell 2500 Dynamic Index
19/03NEXIMMUNE, INC.(NASDAQGM : NEXI) added to Russell 2000 Growth-Dynamic Index
19/03NEXIMMUNE, INC.(NASDAQGM : NEXI) added to Russell 2000 Value-Dynamic Index
19/03NEXIMMUNE, INC.(NASDAQGM : NEXI) added to Russell 2500 Value-Dynamic Index
19/03NEXIMMUNE, INC.(NASDAQGM : NEXI) added to Russell 2000 Dynamic Index
19/03NEXIMMUNE, INC.(NASDAQGM : NEXI) added to Russell 3000 Index
19/03NEXIMMUNE, INC.(NASDAQGM : NEXI) added to Russell 2000 Index
19/03NEXIMMUNE, INC.(NASDAQGM : NEXI) added to Russell 2500 Value Index
19/03NEXIMMUNE, INC.(NASDAQGM : NEXI) added to Russell 3000 Growth Index
19/03NEXIMMUNE, INC.(NASDAQGM : NEXI) added to Russell Microcap Index
19/03NEXIMMUNE, INC.(NASDAQGM : NEXI) added to Russell Small Cap Comp Value Index
19/03NEXIMMUNE, INC.(NASDAQGM : NEXI) added to Russell 3000 Value Index
19/03NEXIMMUNE, INC.(NASDAQGM : NEXI) added to Russell 2500 Growth Index
19/03NEXIMMUNE, INC.(NASDAQGM : NEXI) added to Russell Microcap Value Index
19/03NEXIMMUNE, INC.(NASDAQGM : NEXI) added to Russell 3000E Value Index
19/03NEXIMMUNE, INC.(NASDAQGM : NEXI) added to Russell 3000E Growth Index
19/03NEXIMMUNE, INC.(NASDAQGM : NEXI) added to Russell Small Cap Comp Growth Index
19/03NEXIMMUNE, INC.(NASDAQGM : NEXI) added to Russell Small Cap Completeness Index
19/03NEXIMMUNE, INC.(NASDAQGM : NEXI) added to Russell 2000 Growth Index
02/03NexImmune to Present at the 2021 Barclays Global Healthcare Conference
23/02NEXIMMUNE : Barer & Son Capital and Hibiscus Capital Management Announce Successful Initia..
18/02NEXIMMUNE, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other E..
18/02NexImmune Announces Closing of Upsized Initial Public Offering and Full Exercise of Und..
16/02NEXIMMUNE, INC.(NASDAQGM : NEXI) added to NASDAQ Composite Index
12/02NexImmune Announces Pricing of Upsized Initial Public Offering
11/02NexImmune, Inc. has completed an IPO in the amount of $110.007 million.
19/01NexImmune Appoints Grant Verstandig as New Board Member
19/01NexImmune, Inc. has filed an IPO in the amount of $86.25 million.
19/01NexImmune, Inc. Auditor Raises 'Going Concern' Doubt
18/01Neximmune Names Robert Knight as Chief Medical Officer
04/01Neximmune Announces Executive Changes
2020Neximmune Announces Preliminary Results from Neximmune’s Phase 1/2 Trial of NEXI-001 in..
2020Neximmune to Highlight Preliminary Results from Phase 1/2 Trial of NEXI-001 Via Oral Pr..
2020NexImmune Establishes Research Initiative with City of Hope to Focus on Novel Immunothe..
2020Neximmune, Inc. Announces Dosing of First Patient in NexImmune Phase 1/2 Clinical Trial..
2020NexImmune Completes Dosing of First Cohort in Phase 1/2 Clinical Trial of NEXI-001 in R..
2020NexImmune, Inc. Announces Executive Appointments
2019NexImmune Receives IND Clearance for Phase 1/2 Trial in Relapsed / Refractory Multiple ..
2019NexImmune Appoints Sol Barer as Chairman of the Board of Directors
1  2Volgende